Pregnant women with mechanical heart valves are an ultrahigh-risk group, in whom all anticoagulant options pose maternal and/or fetal risks. It is unclear why the authors of the recent update 1 selected 4 studies, neither the most recent nor of the highest quality, to give a warfarin embryopathy rate of 1.6%. This anomaly rate is not supported by evidence in their Table 1 (3.9% of all pregnancies and 7.4% of livebirths) or by a recent systematic review (6.4% increasing to 10.2% in prospective studies). 2 Furthermore, in the Vitale et al 3 study, which reported the low anomaly rate with warfarin doses of Ͻ5 mg, women in 43% of pregnancies required Ͼ5 mg warfarin, and among these 25 pregnancies, only 6 babies survived; of these 6 babies, 3 had anomalies. The clinician should be cognizant of the high rate of late fetal losses and neonatal deaths associated with warfarin, an issue of particular concern to women. In the systematic review, late fetal losses or neonatal deaths in warfarin-exposed pregnancies occurred in 8.8% of pregnancies and 11.7% of births, 10-fold that expected in a general population. 2 A similar rate of 13.6% was found in 3 studies (nϭ103) published after the final date for inclusion in that review. Consequently, despite warfarin being associated with a lower rate of pregnancy-associated valve thrombosis, some women are reluctant to continue taking warfarin while pregnant.
Response
We thank McLintock and coworkers for their interest in our article. They have raised several issues.
1. They have dismissed 4 studies cited in our article as being not of "the highest quality" without providing criteria for their judgment. We presented actual data from each study and emphasized the importance of considering complications in live births.
2. Citing a review by Chan et al, 1 they state fetal loss or neonatal death in "warfarin-exposed pregnancies occurred in 8.8% of pregnancies and 11.7% of births, 10-fold that expected in the general population." It was not possible in the review to discern the values of 8.8% and 11.7% or information about the general population.
Pregnancy and fetal loss varies considerably in the population. Two prospective studies have documented early pregnancy loss rates of 11.0% to 26.9% and spontaneous abortion rates of 9.5% to 12.5%. 2, 3 Moreover, mortality has steadily declined, and in 1991, perinatal (fetal/neonatal) mortality was 12.8%.
It is more appropriate to compare fetal loss in women with prosthetic heart valves receiving warfarin versus those who had no prostheses. In the European study, 4 women with bioprostheses who received no warfarin had a stillbirth rate of 4%, whereas those with mechanical valves who received heparin the first trimester and then warfarin had a stillbirth rate of 1.5% and neonatal death rate of 1.5%.
3. They present some data with homografts but not the 10-to 20-year outcomes of homografts.
4. They criticize the FDA warnings about use of low molecular weight heparin (LMWH). It is not for us to advise physicians in other countries to heed FDA warnings, but in the United States, it is important to do so. They agreed with a panel's "consensus report." 5 Many panel members had disclosures about research grants, support, speakers bureau, and honoraria with many companies, including manufacturers of LMWH; some even had consultant status. In the spirit of disclosure, it would be appropriate to know the following: (1) Who directly and indirectly funded the meeting and publication of the report? (2) Who selected the panel members? (3) Did the panel members receive remuneration for the meeting and/or the publication and, if yes, from whom?
5. Finally, we wish to re-emphasize the need for a randomized trial of LMWH. 2 
